|Articles|August 10, 2022
- Pharmaceutical Executive-08-01-2022
- Volume 42
- Issue 8
Pharmaceutical Executive, August 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive August 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
The Silver Lining Of Innovation in Genetic Medicineover 3 years ago
Navigating the Financial Meltdown for Biopharmaover 3 years ago
The Potential of Proteomicsover 3 years ago
Getting ‘Personal’ With Vaccine Developmentover 3 years ago
A World of Opportunityover 3 years ago
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
2
Travere Therapeutics’ Filspari Receives Full FDA Approval
3
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
4
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
5

